Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04955366 · ClinicalTrials.gov registry record · Phase 2
Abatacept Conversion in Kidney Transplantation
A Phase 2 study of Renal Transplant Recipient, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 1
- Study location
NCT04955366: Active Phase 2 study of Renal Transplant Recipient, sponsored by Emory University.
NCT04955366 is a Phase 2 study of Renal Transplant Recipient that is active but no longer recruiting, run by Emory University. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04955366, a Phase 2 study of Renal Transplant Recipient, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous injections without a decrease in kidney function.The primary objective will be the difference in estimated GFR (eGFR) for abatacept and belatacept groups using a monthly repeated measures model between randomization and 12 months.
Primary Outcome
Difference in estimated GFR (eGFR) for abatacept and belatacept groups using a monthly repeated measures model between randomization and 12 months.
Conditions Studied
Interventions
- DRUG Abatacept
- DRUG Belatacept
Study Locations (1)
Georgia
- Emory University Hospital (EUH) - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-09-22 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What the registry record for NCT04955366 still lists
NCT04955366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Renal Transplant Recipient appearing as the primary indexed condition, and to 2 interventions - of which Abatacept is the first listed.
NCT04955366 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT04955366 about?
NCT04955366 is a clinical study titled "Abatacept Conversion in Kidney Transplantation". This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous injections without a decrease in kidney function.The primary objective ...
What is the current status of trial NCT04955366?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2021-09-22. Estimated completion is 2026-06.
What conditions does trial NCT04955366 study?
This clinical trial studies the following conditions: Renal Transplant Recipient.
What interventions are being tested in trial NCT04955366?
The interventions under investigation include: Abatacept (DRUG), Belatacept (DRUG).
Who is sponsoring clinical trial NCT04955366?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04955366 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplant Recipient
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04955366's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI